Introduction
The role of anomalous signaling of the hepatocyte growth factor (HGF) receptor tyrosine kinase (RTK) Met in human oncogenesis, maintenance of the malignant phenotype and cancer progression has unequivocally been determined for numerous tumors during the last decade. Moreover, aberrant Met function in cancer has been linked to such prototypical and fundamental hallmarks of tumor manifestation as abnormal angiogenesis, local invasion and systemic dissemination (reviewed in To and Tsao, 1998; Haddad et al., 2001; Longati et al., 2001) . Deregulation of Met function that eventually leads to constitutive activation of the receptor's tyrosine kinase domain takes place by almost all known oncogenic activation mechanisms including point mutations. In this respect, Met is among the most mutated receptor tyrosine kinases in human cancer with more than 20 different somatic or germ-line point mutations that have been so far described (Danilkovitch-Miagkova and Zbar, 2002) . Originally, most Met mutations were associated with the relatively rare papillary renal carcinoma . However, mutations were later reported in hepatocellular (Park et al., 1999) and gastric carcinomas (Lee et al., 2000) as well as in squamous cell cancer of the head and neck, where a role for the Met mutation Y1253D in both lymphatic spread (Di Renzo et al., 2000) as well as resistance to radiotherapy (Aebersold et al., 2003) has been suggested. Most recently, Met mutations have been associated with lung cancer .
Recently, a novel pyrrole indolinone compound, SU11274, that targets the ATP-binding site of Met was shown to block HGF-dependent Met activation as well as the oncogenic variant Tpr-Met Wang et al., 2003) . Met inhibition has been associated with inhibition of downstream signaling and biological events typical to Met activity, such as cell motility and branching morphogenesis (Wang et al., 2003) . SU11274 displayed much lower IC 50 values for inhibition of Met, then towards other tyrosine kinases including EGFR, FGFR1 or Src, thus, suggesting its high specificity. SU11274 belongs to a class of smallmolecule RTK inhibitors that exert their activity by competing for the Mg-ATP complex binding pocket, which results in inhibition of kinase activity and subsequent downstream signaling. The most prominent agent belonging to this class of small-molecule inhibitors is Gleevec. Gleevec targets the oncogenic protein BcrAbl (Druker et al., 1996) as well as the Kit and PDGF receptor kinases (Buchdunger et al., 2000) , and has already proven to be a new concept drug for both chronic myelogenous leukemia Talpaz et al., 2002) and gastrointestinal stromal tumors (van Oosterom et al., 2001; Demetri et al., 2002) . However, it has been found that the presence of point mutations in the catalytic kinase domains of either BcrAbl or Kit is a cause for resistance to Gleevec, thus undermining the drug's efficiency (Roumiantsev et al., 2002; De Silva and Reid, 2003) .
Following the experience with Gleevec, we aimed to determine the efficacy of SU11274 towards naturally occurring mutated variants of the Met receptor. In the present work, we provide evidence that SU11274 differentially and selectively inhibits two out of four Met mutations that were studied, while the other two receptor-mutated forms remain resistant to similar compound concentrations. Moreover, we show that receptor inhibition is strictly coupled to inhibition of downstream effectors and various cellular activities that are representative of Met signaling.
Results

SU11274 inhibition of Met signaling is selective for distinct receptor variants
SU11274 has recently emerged as a novel potent and specific prototype Met inhibitor of both wild type and the oncogenic Tpr-Met fusion protein Wang et al., 2003) . At 5 mM, the compound was shown to block deregulated Met activity due to expression of the constitutively activated TPR-Met. In order to further extend the knowledge about the potential of SU11274 to interfere with other types of Met oncogenic signaling, we have focused the present studies on cellular systems with deregulated Met function due to activating point mutations. Four mutated variants that are positioned in different functional locations of the Met kinase were studied: H1112Y -ATP-binding site, L1213V -hinge region, Y1248H -activation loop and M1268T -p þ 1 loop. All of these mutations cause constitutive Met phosphorylation and have been implicated in various transformation activities (Jeffers et al., 1997 (Jeffers et al., , 1998 Giordano et al., 2000) . Suggested specific roles for part of these mutations have already been proposed (Miller et al., 2001; Danilkovitch-Miagkova and Zbar, 2002) . To examine the capacity of SU11274 to inhibit the constitutive tyrosine phosphorylation displayed by the Met mutants, NIH3T3 cells that stably express the mutant receptor variants were exposed to increasing concentrations of the inhibitor for 16 h. The status of Met phosphorylation was determined by Western blotting using antiphospho-Met-specific antibodies that exclusively recognize the b subunit of the receptor only when tyrosines at positions 1252 and 1253 are phosphorylated. As the results show (Figure 1 ), mutants H1112Y and M1286T are both sensitive to SU11274. A decrease in Met tyrosine autophosphorylation could already be detected at a concentration of 250 nM, and as the concentrations increased the receptor kinase was progressively blocked.
Complete inhibition was observed at 1 and 2 mM for H1112Y and M1268T, respectively. As the results in Figure 1 suggest that the H1112Y variant is more sensitive than M1268T, the IC 50 values for inhibition by SU11274 were determined by quantification of the ECL signals as described in Materials and methods. This yielded values of 270 nM for H1112Y and 800 nM for M1268T. Complete kinase inhibition at 2 mM (data not shown) was also obtained with NIH 3T3 that express the wild-type Met following stimulation by HGF, and with human GTL16 gastric adenocarcinoma cells which overexpress Met (Rege-Cambrin et al., 1992) and in which the receptor is also constitutively activated (IC 50 320 nM). Interestingly, under similar experimental conditions and concentrations of SU11274, we could not detect any inhibition of Met autophosphorylation in the mutated Met variants Y1248H and L1213V, indicating their relative resistance towards the compound.
To evaluate the impact of Met inhibition by SU11274 on downstream pathways, we have chosen to focus on the PI3K/Akt pathway, a signaling cascade initiated by many RTKs, including Met (Graziani et al., 1991) . To that end, the active phosphorylated status of the serine/ threonine protein kinase Akt was studied in the four cellular systems using an antibody specific to serine phosphorylated Akt (serine 473). Our results show that Akt activation was inhibited only in the cells that express the SU11274-sensitive Met forms M1268T and H1112Y ( Figure 1 ). Phosphorylation of Akt decreased in a dose-dependent manner in both cell lines, reaching a significant reduction at 2 mM. In contrast, in cells that express the Y1248H and L1213V mutants, whose Met autophosphorylation was resistant to SU11274 at the S Berthou et al concentrations tested, phosphorylated Akt levels remained unaltered. The observation that decrease in phosphorylated Akt is dependent on a specific Met mutation excludes the possibility that SU11274 might directly inhibit Akt and suggests that downregulation of Akt phosphorylation is strongly dependent on Met inhibition in these cells.
Modulation of cell cycle progression by SU11274 in cells expressing various Met variants
We next sought to confirm if the sensitivity or resistance to SU11274 could also be seen in biological end points such as parameters of cell growth. To accomplish this, effects of SU11274 on cell cycle progression in cells expressing the four Met variants was examined (Figure 2 ). Since 2 mM SU11274 was sufficient to achieve complete inhibition of Met and Akt phosphorylation, this concentration was used to evaluate the effect of the compound on cell cycle progression. The data demonstrate that the cells that express the two sensitive Met mutations exhibited a dramatic reduction of DNA synthesis. Thus, the percentage of cells in S phase was reduced by 7.47-fold, from 22.4 to 3, and by 4.65-fold, from 20 to 4.3, in the M1268T and H1112Y mutants, respectively. The decrease in S-phase populations was accompanied by an expected concomitant increase of the G0/G1 fraction (increasing from 66 to 89.1% and from 73.4 to 94%, for M1268T and H1112Y mutants, respectively) suggesting a strong G1 cell arrest. Furthermore, SU11274 also reduced the number of cells in the G2/M phase (from 11.5 to 7.9% for M1268T and from 6.6 to 1.7% for H1112Y). In the same study, the control NIH3T3 cells transfected with the empty pMex vector exhibited a 1.3-fold reduction in S-phase content following treatment with 2 mM SU11274 (data not shown). This might be explained by the fact that the cells express Met, as was previously shown (Jeffers et al., 1997) . Since the same cells produce small amounts of HGF as well (Jeffers et al., 1997) , SU11274 may interfere with an autocrine loop, which may contribute to their proliferation rate. However, some nonspecific inhibition of other targets that contribute to 3T3 cell proliferation could not be ruled out. The relative mild sensitivity of the control cells to the drug is probably overshadowed in the presence of strong drivers of proliferation which are resistant to the drug, such as the Y1248H and L1213V Met variants. Taken together, these data indicate that the compound induces a strong G1 arrest in the cells expressing sensitive Met mutants.
In contrast, the two resistant Met variants Y1248H and L1213V did not exhibit any significant changes in cell cycle distribution under the same conditions (S phasefrom 23.2 to 23% and 27.9 to 25.2%, for Y1248H and L1213V, respectively).
Effect of SU11274 on cell morphology and motility in cells expressing different Met mutants
Deregulated Met activation is strongly implicated in cellular transformation and enhanced motility. Constitutively activated mutated Met forms have already been shown to mediate such activities when ectopically expressed in various cellular systems (Bardelli et al., 1998; Lorenzato et al., 2002) . We next studied if exposure to SU11274 will selectively affect the motility and transformed morphologies of the NIH3T3 cell lines expressing the Met mutants. The cells were examined following exposure to 2 mM SU11274 for 16 h (Figure 3a) . The cells expressing the sensitive Met variants M1268T and H1112H exhibited considerable morphological changes upon exposure to the compound. Cells from both lines became much flatter compared with the control, non-treated cells. Their phenotype reverted from that of highly transformed cells to a fibroblastoid morphology characteristic of NIH3T3 cells, with better cell-to-cell contact. In contrast, the SU11274-resistant mutations L1213V and Y1248H appeared almost completely unchanged. The cells retained their highly transformed phenotype that is characterized by a round, dedifferentiated shape, and accompanied by spontaneous foci formation. Cell motility was evaluated using the in vitro woundhealing/scratch assay, which has been previously used to show enhanced cellular motility that is facilitated by Met mutated variants (Lorenzato et al., 2002) . Predictably, the motility of the responsive Met variants M1268T and H1112Y was significantly hampered by exposure to the inhibitor, as demonstrated by the fact that the scratch was still obvious after 24 h. In contrast, no difference was observed for the resistant variants Y1248H and L1213V upon treatment with SU11274 ( Figure 3b) . To estimate the relative contribution of inhibition of cell proliferation to the results of the migration assay, we determined cell numbers by manual counting after 24 h exposure to 2 mM SU11274. Reductions of 22 and 20% for the M1268T and H1112Y cell lines were observed, respectively (data not shown). Thus, inhibition of cellular proliferation may also contribute to the effects seen in the migration assay. However, this mechanism appears to only be a minor contributor to inhibition of wound healing by SU11274, and the main mechanism responsible for the observation is most likely to be inhibition of molecular pathways downstream Met that control cellular motility.
Structural basis for the differential interaction of SU11274 with various Met mutants
To understand the differential effects of SU11274 on the kinase activity of the Met mutants, a homology model was constructed from the coordinates of the FGFR1 crystal structure (Mohammadi et al., 1997) , and SU11274 was docked into the ATP-binding site (Figure 4) . The side chains of the mutated amino acids are shown as extending from the ribbon structure that represents the peptide backbone. This homology model suggests that H1112, L1213, Y1248 and M1268 are not in very close proximity to the space that SU11274 is expected to occupy. Consequently, they would not be expected to have a direct impact on the interaction of the compound with the ATP-binding pocket. Therefore, Figure 3 (a) SU11274 selectively reverts transformed morphologies of NIH3T3 cell lines that stably express various Met mutation variants. Cells were treated overnight with 2 mM SU11274 and morphological changes were observed with an inverted microscope. (b) SU11274 selectively inhibits spontaneous HGF-independent cell motility in a wound-healing assay. NIH3T3 cell lines stably expressing various Met mutations were grown to confluence. A portion of the monolayer was scratched with a pipette tip (t ¼ 0) and then healing of the wound was observed after 24 h incubation in the presence or absence of 2 mM SU11274 (t ¼ 24). Cells were stained with crystal violet
Selective inhibition pattern of SU11274
S Berthou et al it may not be surprising that SU11274 was still able to inhibit Met kinase containing the H1112Y and M1268T mutations. Y1248 is located within the activation loop, whose exact location cannot be predicted due to its flexibility (Schiering et al., 2003) . Although it is depicted in Figure 4 as pointing away from the ATP-binding pocket and SU11274, the observation that the compound cannot inhibit Met kinase when Y1248 is mutated to His suggests that the activation loop may be in closer proximity to the site at which SU11274 binds. In the recently published crystal structure of Met (Schiering et al., 2003) , the position of the activation loop could not be determined in the apo-enzyme. However, when the kinase inhibitor K252a was bound into the ATPbinding site, the activation loop became ordered and assumed a conformation different from that of other active or inactive kinases (Schiering et al., 2003) . It is not yet known if SU11274 would affect the structure of the activation loop in a similar manner.
There is no obvious explanation for the insensitivity of the L1213 mutant. We could speculate on possible reasons such as allosteric perturbation of the structure, but without crystallization data on the mutant forms of Met used in these studies there appears to be little reason to make hypotheses at the present time. Furthermore, in mutagenesis studies on BCR-ABL, Azam et al. (2003) demonstrated that mutations throughout the kinase domain alter sensitivity to Gleevec in ways that are not readily predictable, even when the crystal structure of the native kinase domain bound to a compound is known. Therefore, it will be necessary for us to wait for the crystal structures of these mutant forms of Met to be solved to better understand how the mutations that induce resistance to SU11274 affect the three-dimensional structure of the kinase.
Discussion
In summary, Met is among the most deregulated RTK systems in human cancer. Several studies that have been published over the recent years describe Met/HGF signaling suppression by various approaches and strongly emphasize the rationale for the targeting of this RTK system in cancer therapy (Maulik et al., 2002) . SU11274 could be considered as a breakthrough in this respect, since it is the first small molecule that was designed to specifically inactivate Met kinase function. Our results show that some forms of Met that are activated by point mutations can also be inhibited effectively by this inhibitor. However, the results also disclose the complexity of the system by showing that not every mutated Met variant could be inhibited. This finding may lead to several practical conclusions. Foremost, the precedence concerning the role of point mutations as a major resistance mechanism to drugs like Gleevec could be extended to Met kinase inhibitors. In order to circumvent this phenomenon, it will be essential to deepen our understanding of the three-dimensional structures of mutant tyrosine kinase domains of candidate targets by crystallographic studies, which will assist in the development of inhibitors of the resistant variants.
Concerning clinical implications, the results obtained with both SU11274 and with Gleevec imply that treatment success or failure may depend on the type of mutation that might exist in an individual tumor. Thus, in addition to the pre-selection of patients by genetic screening of tumor tissue, as recently suggested for radiotherapy (Aebersold et al., 2003) , profiling the complete panel of mutated variants for an oncogene like Met, with respect to sensitivity/resistance to a given compound, will probably become an essential step for selecting of the appropriate tumor therapy. Finally, selective inhibitors like SU11274 and the large cohort of naturally occurring Met mutations could prove to be a most useful experimental tool for studying the roles of key residues in the kinase domain of this receptor. It is anticipated that studies in which various Met variants will be crystallized in the presence of SU11274 will yield exciting results that will shed new light on the fine structure-function relationship of this RTK.
Materials and methods
Cell culture
NIH 3T3 cell lines that stably express the Met mutated variants (M1268T, Y1248H, H1112Y, L1213V) were provided by Dr Laura Schmidt (NCI, Frederick, MD, USA). Cells were maintained in DMEM (GIBCO, Invitrogen Corp.) supplemented with 10% FCS (Sigma), antibiotic-antimycotic (penicillin 100 U/ml, streptomycin sulfate 100 U/ml, amphotericin B as Fungizone 0.25 mg/ml; GIBCO, Invitrogen Corp.) and Figure 4 Homology model of Met Kinase. The homology model of Met kinase was based on the crystal structure of FGFR1. The predicted structure of the protein backbone is shown as a blue ribbon. The activation loop is colored red to indicate that the prediction of the structure for this segment is less certain than that of the rest of the kinase domain, due to lack of homology with FGFR1 in this region, as well as inherent flexibility associated with kinase activation loops. Amino-acid side chains corresponding to mutation sites mentioned in the text are shown extending from the ribbon (C, green; N, blue; O, red; S, yellow) . SU11274 (C, yellow; N, blue; O, red; S, yellow; Cl, green) is shown docked into the ATPbinding pocket, as expected for an indolinone kinase inhibitor 
Antibodies
The rabbit polyclonal anti-phospho-Met, anti-phospho-Akt1 (recognizes also phosphoserine 473 of Akt2 and Akt3) and anti-Akt antibodies were all purchased from Cell Signaling (Cell Signaling Technology, Inc., Beverly, MA, USA). The rabbit polyclonal anti-Met antibody was purchased from Santa Cruz (SP260, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The rabbit polyclonal anti-beta-actin antibody was purchased from SIGMA (Fluka Chemie, Buchs, CH, USA).
Morphology
Cells were seeded on eight-chamber slides in medium containing 10% FCS and grown for 24 h to reach 40% confluence. Then, cells were treated with 2 mM of SU11274 (see text and Figure 3 ). After overnight incubation, changes in the morphology were observed by microscopy, documented with a Leica DC 300F camera and processed with the Leica IM-50 software.
Cell cycle analysis by cytometry
Cells were treated overnight with 2 mM SU11274. Before fixation with 70% ethanol in PBS, pH 7.4, cell number was adjusted to a density of 1 Â 10 6 cells/ml. Then, 1 Â 10 6 fixed cells were treated with 0.2 mg/ml ribonuclease A (SIGMA) in PBS for 15 min at 371C and stained on ice with 20 mg/ml of propidium iodide in PBS for half an hour before analysis with a FACSscan (Becton Dickinson, San Diego, CA, USA). The result is the mean of three independent experiments and was processed in Excel (Microsoft, Inc.).
Met activation and signal transduction analysis
Cells were treated for 16 h with various concentrations of SU11274 (see text and Figures 1 and 4 ). Cells were lysed in lysis buffer (1% Triton X-100, 0.5% Nonident NP-40, 1 mM EGTA, 1 mM EDTA, 150 mM NaCl, 10 mM Tris-HCl, 1 mM Na 3 VO 4 , 10 mM NaF, 1 mM ZnCl 2 , 50 mM Na 2 MoO 4 , 1.4 mg/ ml aprotinin, 35 ng/ml PMSF, a cocktail of proteases inhibitor (Complete Mini, Roche)). Cell extracts were cleared by centrifugation. Total protein concentration was determined using the BioRad protein quantification reagent (Bio-Rad Laboratories, Inc.). In all, 100 mg of total proteins were resolved by SDS-PAGE on a 7% gel under reducing conditions (Invitrogen, Corp.). Separated proteins were transferred onto a PVDF membrane and analysed by Western blotting (Invitrogen, Corp.). Detection of secondary antibodies was performed using the ECL kit (Amersham Pharmacia Biotech, UK). Quantification of ECL signals was performed using Quantity One s software (BioRad Laboratories, Inc.) and data were processed by Excel (Microsoft s ) to obtain IC 50 values for Met kinase inhibition by SU11274.
Wound-healing assay NIH 3T3 stably expressing the mutant Met receptors were seeded in a six-well plate (5 Â 10 5 cells/well) and treated with 2 mM SU11274. After 4 h of treatment, a portion of the monolayer was scratched with a pipette tip. Cells were examined for resealing of the 'wounded' monolayer after 24 h of incubation. The cells were stained with 0.005% crystal violet in PBS, pH 7.4, for 5 min before photo-documentation with a Leica DC 300F camera and analysis with Leica IM-50 software. In parallel, for each of the cell lines, a similar initial number of cells were incubated with 2 mM SU11274 and the number of cells was counted after 24 h.
Homology model of met TK
To understand the differential effects of SU11274 on the kinase activity of the Met mutants, a homology model was constructed from the coordinates of the FGFR1 crystal structure (Mohammadi et al., 1997) , and SU11274 was docked into the ATP-binding site (Figure 4) . The side chains of the mutated amino acids are shown as extending from the ribbon structure that represents the peptide backbone.
Abbreviations HGF, hepatocyte growth factor; FGFR1, fibroblast growth factor receptor 1; PDGFR, platelet-derived growth factor receptor; Trk, tropomyosin receptor kinase; Ret, rearranged during transformation; PI3K, phosphotidylinisitol-3-OH kinase; SDS-PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis; FCS, fetal calf serum.
